How Long Does a B12 Injection Stay in Your System? What Studies Describe

"How long does a B12 injection stay in your system" has no single number attached to it, because cobalamin behaves differently from most injected small molecules. This page summarises what the cited literature describes about absorption, distribution, storage and excretion of injected vitamin B12, what it says about measurement and laboratory interference, and which factors the same literature reports as altering cobalamin handling. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, test result or treatment. For the general framework used across this site, see how long peptides stay in your system, and for background on the compound itself see B12 injection.

Answer first: three different clocks

Discussions of cobalamin pharmacokinetics in the cited literature separate three timescales that are frequently conflated in casual summaries:

• Minutes to hours. A parenteral dose enters the circulation directly, bypassing the gastric and intrinsic-factor steps that a 2023 overview of vitamin B12 described as governing absorption of dietary and oral cobalamin (https://pubmed.ncbi.nlm.nih.gov/32644558/).
• Hours to days. Cobalamin that exceeds the carrying capacity of plasma binding proteins is not retained; the kidney is the route of loss. In the cyanide-antidote setting, researchers reviewing hydroxocobalamin reported visible red discolouration of urine and skin persisting for days after high-dose intravenous administration (https://pubmed.ncbi.nlm.nih.gov/23163594/).
• Weeks to months. The fraction that is bound and taken up into tissue, particularly the liver, leaves far more slowly. A 2003 review of elevated cobalamin levels in blood reported that high serum cobalamin may reflect administered cobalamin as well as disease states such as liver disease and myeloproliferative disorders (https://pubmed.ncbi.nlm.nih.gov/14636871/).

So the honest answer is that the peak passes quickly, the excess is excreted quickly, and the retained portion persists far longer than any injection interval.

What "half-life" means — and why one number is misleading

A plasma half-life describes the time for a concentration to fall by half during a single, well-behaved elimination phase. Cobalamin does not fit that model cleanly. It is distributed between two carrier proteins, concentrated in hepatic stores, and recycled through the enterohepatic circulation, so serum concentration after an injection reflects distribution and redistribution at least as much as elimination.

None of the papers in this page's verified citation set reported a single numeric elimination half-life for injected cyanocobalamin in humans. Rather than invent one, this page states the mechanisms that the cited sources do describe. The 2023 vitamin B12 overview described cobalamin's dependence on intrinsic factor and receptor-mediated uptake for oral absorption and its role as a cofactor in methionine and methylmalonyl-CoA metabolism (https://pubmed.ncbi.nlm.nih.gov/32644558/), and the hydroxocobalamin review reported that hydroxocobalamin binds cyanide to form cyanocobalamin, which is then excreted in the urine (https://pubmed.ncbi.nlm.nih.gov/23163594/). Both observations point to the same structure: binding determines retention, and the unbound surplus goes to urine.

Where an injected dose goes

Binding capacity sets the ceiling

Circulating cobalamin travels bound to transcobalamin and haptocorrin. When an injected quantity exceeds that binding capacity, the surplus is filtered and lost. The 2003 review of elevated blood cobalamin reported that abnormally high measured cobalamin arises not only from administration but from altered binding-protein states associated with hepatic and haematological disease, which is why a high serum number is not self-explanatory (https://pubmed.ncbi.nlm.nih.gov/14636871/).

Storage slows everything down

The liver holds the body's largest cobalamin reserve, and the 2023 overview described deficiency as developing over an extended period once absorption fails, rather than within days (https://pubmed.ncbi.nlm.nih.gov/32644558/). The practical consequence for the "how long" question is that an injection can continue to influence measured serum cobalamin and functional markers long after the acute peak has resolved.

Reported timeline at a glance

Detectability: what is and is not tested for

Standard workplace and athletic drug-screening panels target drugs of abuse and their metabolites. Cobalamin is a dietary vitamin and is not an analyte on those panels; there is no "B12 test" within a drugs-of-abuse screen, and nothing in the cited literature describes cobalamin producing a positive result for a drug of abuse.

What is detectable is cobalamin itself, on a serum vitamin B12 assay. The 2003 review reported that elevated serum cobalamin has recognised clinical significance and multiple causes, meaning a raised value after administration is expected rather than anomalous (https://pubmed.ncbi.nlm.nih.gov/14636871/). A separate and better-documented issue is assay interference: researchers reviewing hydroxocobalamin in cyanide poisoning reported that its deep red colour interferes with colorimetric laboratory measurements and causes discolouration of plasma and urine (https://pubmed.ncbi.nlm.nih.gov/23163594/). That is a laboratory-chemistry phenomenon, not a toxicology-screening one.

Functional status is assessed with different markers. The 2023 nitrous oxide review reported that nitrous oxide inactivates cobalamin by oxidising its cobalt centre and impairs methionine synthase, producing metabolic and neurological consequences — a situation in which measured cobalamin can be unhelpful because the molecule present is not functional (https://pubmed.ncbi.nlm.nih.gov/38133363/). Homocysteine is one of the downstream markers used in this metabolic pathway, and a review of homocysteine and renal disease reported that homocysteine concentrations are elevated in renal impairment, independent of vitamin status (https://pubmed.ncbi.nlm.nih.gov/11011849/).

Factors reported to change cobalamin handling

Renal function

Because the surplus of an injected dose leaves in urine, renal function is a logical determinant of how fast that surplus disappears. The cited renal literature addressed homocysteine rather than cobalamin clearance directly, reporting elevated homocysteine in renal disease (https://pubmed.ncbi.nlm.nih.gov/11011849/); readers should treat the extension to cobalamin excretion rates as mechanistic reasoning, not a measured finding.

Chemical form

Cyanocobalamin, hydroxocobalamin, methylcobalamin and adenosylcobalamin differ in the upper axial ligand on the cobalt atom, and that difference affects protein binding and retention. The strongest form-specific pharmacokinetic description in this citation set concerns hydroxocobalamin, where researchers reported cyanide binding, conversion to cyanocobalamin and urinary excretion, alongside prolonged red discolouration (https://pubmed.ncbi.nlm.nih.gov/23163594/). A 2016 review of therapeutic approaches to homocystinuria described cobalamin-based therapy among the treatment strategies used in these inherited metabolic disorders (https://pubmed.ncbi.nlm.nih.gov/27059523/).

Concurrent exposures

Nitrous oxide is the clearest documented example of an exposure that changes what cobalamin does in the body rather than how long it stays: the study reviewing nitrous oxide abuse reported inactivation of cobalamin and disruption of one-carbon metabolism (https://pubmed.ncbi.nlm.nih.gov/38133363/). Gastric acid-suppressing therapy affects the oral, not the injected, route; a 2025 review examined proton pump inhibitor pharmacodynamics, pharmacokinetics, drug interactions and toxicity (https://pubmed.ncbi.nlm.nih.gov/40771914/), and the acid- and intrinsic-factor-dependent steps it would act on are the same steps the 2023 vitamin B12 overview described for dietary cobalamin (https://pubmed.ncbi.nlm.nih.gov/32644558/).

Baseline status and intake

How much of an injected dose is retained depends partly on how depleted the stores are. Dietary intake sits upstream of that: a 2024 case-study model assessing the nutrient composition of a carnivore diet reported nutrient intakes including vitamin B12 from animal-source foods (https://pubmed.ncbi.nlm.nih.gov/39796574/), and a 2022 review of thyroid, diet and alternative approaches examined dietary and supplement practices promoted in endocrine contexts (https://pubmed.ncbi.nlm.nih.gov/35952387/).

What general peptide pharmacokinetics does and does not transfer

Vitamin B12 is not a peptide. It is a cobalt-containing corrinoid, and it is more stable in the gut than a peptide of comparable size. The reason the comparison appears at all is that both classes are usually given parenterally for the same structural reason — the oral route is inefficient. A 2021 review of oral delivery of proteins and peptides described the enzymatic degradation and epithelial permeability barriers that limit oral bioavailability of these molecules (https://pubmed.ncbi.nlm.nih.gov/34522593/). For cobalamin the limiting step is different: the 2023 overview described a receptor- and intrinsic-factor-dependent absorption pathway with a saturable capacity (https://pubmed.ncbi.nlm.nih.gov/32644558/).

The practical divergence matters for the "how long" question. Most injectable peptides are cleared within hours to days and leave no reservoir. Cobalamin has a storage compartment, so its system residence is measured on a different scale entirely.

Observations on Tolerability and Laboratory Effects: What Studies Report

Within this citation set, the most consistently reported non-therapeutic observations relate to colour and measurement rather than systemic toxicity. Researchers reviewing hydroxocobalamin reported red discolouration of skin, mucous membranes and urine and interference with colorimetric laboratory assays after high-dose intravenous administration in cyanide poisoning (https://pubmed.ncbi.nlm.nih.gov/23163594/). Separately, the 2003 review reported that elevated serum cobalamin is clinically meaningful because it can flag underlying hepatic or myeloproliferative disease rather than simply reflecting supplementation (https://pubmed.ncbi.nlm.nih.gov/14636871/). The nitrous oxide review reported neurological and metabolic harm arising from cobalamin inactivation rather than from cobalamin administration itself (https://pubmed.ncbi.nlm.nih.gov/38133363/).

Limits of this evidence

1. No paper in this verified set reported a numeric plasma half-life for injected cyanocobalamin, so no number is given here.
2. The most detailed parenteral pharmacokinetic description available concerns hydroxocobalamin at antidote doses in cyanide poisoning (https://pubmed.ncbi.nlm.nih.gov/23163594/), a setting far removed from routine supplementation.
3. Statements about renal clearance of cobalamin are mechanistic extrapolation; the cited renal paper measured homocysteine in renal disease (https://pubmed.ncbi.nlm.nih.gov/11011849/).
4. Peptide-delivery principles are included as general science and are explicitly labelled as such (https://pubmed.ncbi.nlm.nih.gov/34522593/).

References

• Vitamin B12 (Cobalamin) (2023)
• Significance of elevated cobalamin (vitamin B12) levels in blood (Clinical Biochemistry, 2003)
• Hydroxocobalamin in cyanide poisoning (Clinical Toxicology, 2012)
• Nitrous Oxide Abuse: Clinical Outcomes, Pharmacology, Pharmacokinetics, Toxicity and Impact on Metabolism (Toxics, 2023)
• Homocystinuria: Therapeutic approach (Clinica Chimica Acta, 2016)
• Homocysteine and renal disease (Seminars in Thrombosis and Hemostasis, 2000)
• Pharmacodynamics, pharmacokinetics, interactions with other drugs, toxicity and clinical effectiveness of proton pump inhibitors (Frontiers in Pharmacology, 2025)
• Oral delivery of proteins and peptides: Challenges, status quo and future perspectives (Acta Pharmaceutica Sinica B, 2021)
• Assessing the Nutrient Composition of a Carnivore Diet: A Case Study Model (Nutrients, 2024)
• Thyroid, Diet, and Alternative Approaches (The Journal of Clinical Endocrinology and Metabolism, 2022)